Learn more

NINGBO MEILI RENSHENG MEDICINE BIOTECHNOLOGY DEV CO LTD

Overview
  • Total Patents
    21
  • GoodIP Patent Rank
    77,030
About

NINGBO MEILI RENSHENG MEDICINE BIOTECHNOLOGY DEV CO LTD has a total of 21 patent applications. Its first patent ever was published in 2015. It filed its patents most often in China. Its main competitors in its focus markets pharmaceuticals, medical technology and biotechnology are NINGBO ACADEMY OF SCIENCE AND TECH FOR INSPECTION AND QUARANTINE, HAPLNSCIENCE INC and SHUBER ANTHONY P.

Patent filings in countries

World map showing NINGBO MEILI RENSHENG MEDICINE BIOTECHNOLOGY DEV CO LTDs patent filings in countries
# Country Total Patents
#1 China 21

Patent filings per year

Chart showing NINGBO MEILI RENSHENG MEDICINE BIOTECHNOLOGY DEV CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Tian Xiaoli 21

Latest patents

Publication Filing date Title
CN106754710A NY-ESO-1 mediates the external combination of itself immature dendritic cells by paradigmatic structure domain
CN106725967A The foundation of the internal ischemia model that one arteria cerebri media blocks completely
CN106771224A The mouse internal antibody that TLR4 mediations NY-ESO-1 causes reacts
CN106729697A NY-ESO-1 plays the role of as enhancing CA9 immunogenic molecules adjuvants
CN106755114A NY-ESO-1 mediates its own mouse internal antibody for causing to react by paradigmatic structure domain
CN106729766A Effect of the passages of CaV2 1 in the ischaemic model of Ca2+ dependences
CN106729698A NY-ESO-1 plays the role of as enhancing Art v1 (wtArt) anaphylactogen immune response molecule adjuvant
CN106754709A Calprotectin participates in NY-ESO-1 and is combined with DC cells in vitro in marrow
CN106729767A [Ca2+] i reductions in ischemia model in vitro of the mutant mouses of 1 α of CaV2 1
CN106725968A One foundation of the external ischemia model of the oxygen glucose deprivation in hippocampal slices
CN106771225A TLR4 is related to the external combination of NY-ESO-1 and DC cells
CN106727658A The purposes of polyinosinic acid, imiquimod and GDQ in virus immunity mouse model is built
CN106729758A PolyI:C is to lung's antimicrobial defenses in long-term adverse effect
CN106729762A PolyI:C causes the death rate of the Secondary bacterial infections host for depending on I type interferon to increase
CN106729761A TLR3 and Cardif paths contribute to PolyI:C to induce host to the neurological susceptibility of bacterium
CN106729714A Polyinosinic acid is administered and the relation between IFNI expression
CN106729760A Polyinosinic acid increases the sensitiveness of the secondary pneumonia caused by gram-positive bacterium
CN106729764A A kind of structure of virus immunity mouse model
CN106729765A The activation of TLR3 and RIG-I signal paths contributes to the bacterium removing obstacles effect that polyinosinic acid causes
CN106729759A PolyI:C is to lung's antimicrobial defenses in long-term adverse effect